Encysive Pharmaceuticals (formerly Texas Biotechnology Corporation), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for our expertise in small molecule drug development and vascular biology. Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III development of the endothelin antagonist, sitaxsentan, for pulmonary arterial hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in Phase II development with the selectin antagonist bimosiamose in asthma, psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other research and development programs ongoing for a range of cardiovascular and inflammatory diseases. Click Here for Management

Shareholder Information Exchange NASDAQ Global Market (.O) Stock Quotes and Charts (ENCY) 2.35  As of 6/9/2008 4:00 PM Minimum 20 minutes delayed Listed Security ENCY Common Stock Corporate Information 4848 Loop Central Drive, 7th Floor Houston, TX 77081 Phone 713-796-8822 Fax 713-796-8232 http://www.encysive.com Transfer Agent The Bank of New York 101 Barclay New York, New York 10286 Independent Accountants KPMG LLP Houston, TX

Copyright © 1998-2003 MarketWatch.com Inc. User agreement applies.
Historical and current end-of-day data provided by Interactive Data Corp.
Intraday data is at least 20-minutes delayed. All times are EDT.
Intraday data provided by S&P Comstock and subject to terms of use.